EUVIMEDEUVIMED entdecken
Crossref

Peri-procedural outcome according to VARC-3 criteria and hemodynamic mid-term follow-up after Valve-in-valve transcatheter aortic valve replacement for failed aortic bioprosthesis

Kensuke Takagi, Naonori Kawamoto, Yuki Irie, Takashi Kakuta, Yasuhide Asaumi, Atsushi Okada, Makoto Amaki, Takeshi Kitai, Hideaki Kanzaki, Chisato Izumi, Satsuki Fukushima, Kazuhiro Yamamoto und 2 weitere

Cardiovascular Intervention and Therapeutics · 2025

DOI: 10.1007/s12928-024-01063-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Intervention and Therapeutics, 2025. Verfasst von Kensuke Takagi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan. takagi.kens…. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Bioprosthesis, Heart Valve Prosthesis, Aortic Valve. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the widespread adoption of valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) for patients with failed aortic bioprosthesis, the effectiveness of this treatment for Japanese patients frequently associated with small aortic annuli remains unclear. From December-2011 to October-2022, 41 consecutive patients undergoing VIV-TAVR were enrolled in this study. The endpoints were technical success, device success, early safety, and two-year mortality according to implanted surgical valve size (small valves: 19-mm and 21-mm, n = 23; large valves: 23-mm and 25-mm, n = 18). The patient population had a mean age of 80.5 years, 46.3% male. Technical success, device success, and early safety rates were 100%, 70.7%, and 87.8%, respectively. There was no significant increase in the transprosthetic gradient throughout the follow-up (mean pressure gradient pre-VIV, post-VIV, at one-year, and at two-year; 37.0 mmHg, 16.5 mmHg, 15.0 mmHg, and 12.0 mmHg, respectively). While technical success and two-year mortality were comparable (87.5% vs. 86.7%, log-rank p = 0.816), device success was significantly lower in the small valves than in the large valves (56.5% vs. 88.9%, p = 0.038). Early safety trended lower in the small valves. Valve hemodynamic performance improved in both groups, but severe prosthesis-patient mismatch was more common in the small valves. VIV-TAVR demonstrated acceptable technical performance and relatively low mid-term mortality in this Japanese population, irrespective of aortic annular size. However, device success and early safety were significantly worse in patients with small valves than in those with large valves.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementBioprosthesisHeart Valve ProsthesisAortic ValveAortic Valve StenosisHemodynamicsHumansMaleFemaleAged, 80 and overFollow-Up StudiesAgedProsthesis FailureTreatment OutcomeProsthesis DesignRetrospective Studies

Stichwörter der Autor:innen

Bioprosthetic valve failure (BVF)Prosthesis-patient mismatch (PPM)Structural valve deterioration (SVD)VIV-TAVR

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan. takagi.kensuke@ncvc.go.jp.
  • Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.
  • Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka, 564-8565, Japan.
  • Division of Cardiovascular Medicine, Endocrinology and Metabolism, Tottori University, Tottori, Japan.
  • Department of Advanced Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Zitieren

APA

Takagi, K., Kawamoto, N., Irie, Y., Kakuta, T., Asaumi, Y., Okada, A., Amaki, M., Kitai, T., Kanzaki, H., Izumi, C., Fukushima, S., Yamamoto, K., Noguchi, T., & Fujita, T. (2025). Peri-procedural outcome according to VARC-3 criteria and hemodynamic mid-term follow-up after Valve-in-valve transcatheter aortic valve replacement for failed aortic bioprosthesis. Cardiovascular Intervention and Therapeutics. https://doi.org/10.1007/s12928-024-01063-9

Vancouver

Takagi K, Kawamoto N, Irie Y, Kakuta T, Asaumi Y, Okada A, et al. Peri-procedural outcome according to VARC-3 criteria and hemodynamic mid-term follow-up after Valve-in-valve transcatheter aortic valve replacement for failed aortic bioprosthesis. Cardiovascular Intervention and Therapeutics. 2025. doi:10.1007/s12928-024-01063-9

BibTeX
@article{Takagi2025,
  author = {Takagi, Kensuke and Kawamoto, Naonori and Irie, Yuki and Kakuta, Takashi and Asaumi, Yasuhide and Okada, Atsushi and Amaki, Makoto and Kitai, Takeshi and Kanzaki, Hideaki and Izumi, Chisato and Fukushima, Satsuki and Yamamoto, Kazuhiro and Noguchi, Teruo and Fujita, Tomoyuki},
  title = {Peri-procedural outcome according to VARC-3 criteria and hemodynamic mid-term follow-up after Valve-in-valve transcatheter aortic valve replacement for failed aortic bioprosthesis},
  journal = {Cardiovascular Intervention and Therapeutics},
  year = {2025},
  doi = {10.1007/s12928-024-01063-9}
}
Kostenlos starten →